Our Resources | Association for Accessible Medicines

In the News - View AAM CEO Dan Leonard's blog on the essential role generic drugs play during COVID-19

AAM Lobby

Feb 24, 2021 | Rachel Schwartz

AAM Announces 2021 Associate Members

Roadmaps for Ensuring Patient Access to Generic and Biosimilar Medicines: Securing Sustainable Markets

Feb 22, 2021 | Erica Klinger

Roadmaps for Ensuring Patient Access to Generic and Biosimilar Medicines: Securing Sustainable Markets

Secure Our Meds

Feb 22, 2021 | Rachel Schwartz

AAM Outlines Policy Solutions for Sustained Patient Access to Generic and Biosimilar Medicines

Chiquita Brooks-LaSure

Feb 19, 2021 | Rachel Schwartz

AAM Statement on President Biden’s Nomination of Chiquita Brooks-LaSure as CMS Administrator

Potential Savings from Accelerating US Approval of Complex Generics

Feb 9, 2021 | Rachel Schwartz

Complex Generics Could Save the U.S. Health Care System Approximately $1.3 Billion Per Year

Potential Savings from Accelerating US Approval of Complex Generics

Feb 9, 2021 | Erica Klinger

White Paper: Potential Savings from Accelerating U.S. Approval of Complex Generics

Doctors and technology

Feb 5, 2021 | Erica Klinger

Cancer Costs and Options for Care in the United States

Dan Leonard, AAM President and CEO=

Feb 4, 2021 | Dan Leonard

While We Await the Vaccine, We Can Trust in Generic Drugs

My Prescription for Savings. It’s time for Congress to take meaningful action to lower prescription drug costs with the Prescription for Savings. Patients win when market-based competition from FDA-approved generics and biosimilars deliver savings at the pharmacy counter.

Jan 29, 2021 | Kristin Murphy

AAM’s Recommendations to #SecureOurMeds

USA flag with generic medicines

Jan 21, 2021 | Rachel Schwartz

AAM Statement on Biden’s Executive Orders to Strengthen America’s COVID Response

Friendly pharmacist hands a paper bag to young female customer at the checkout counter

Jan 15, 2021 | Rachel Schwartz

AAM and Biosimilars Council Statement on CMS Decision to Update Part D Program

Jan 6, 2021 | Dan Leonard

2021 Generics and Biosimilars Outlook